CLASSYS Valuation
Is A214150 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of A214150 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: A214150 (₩31500) wird über unserer Schätzung des Fair Value (₩28919.12) gehandelt.
Deutlich unter dem Marktwert: A214150 über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A214150?
Other financial metrics that can be useful for relative valuation.
| What is A214150's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₩2.32t |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 12.5x |
| Enterprise Value/EBITDA | 23.9x |
| PEG Ratio | 1.5x |
Price to Earnings Ratio vs Peers
How does A214150's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 23.8x | ||
A085370 Lutronic | 33.1x | 26.4% | ₩949.5b |
A145720 Dentium | 11.6x | 16.4% | ₩1.1t |
A287410 Jeisys Medical | 27x | 28.7% | ₩670.6b |
A336570 WON TECHLtd | 23.3x | 21.7% | ₩906.4b |
A214150 CLASSYS | 31.3x | 20.4% | ₩2.3t |
Price-To-Earnings gegen Gleichaltrige: A214150 ist auf der Grundlage des Price-To-Earnings Verhältnisses (26x) im Vergleich zum Durchschnitt der Vergleichsgruppe (22.6x) teuer.
Price to Earnings Ratio vs Industry
How does A214150's PE Ratio compare vs other companies in the KR Medical Equipment Industry?
Price-To-Earnings gegen Industrie: A214150 ist teuer, wenn man sein Price-To-Earnings Verhältnis (22.8x) mit dem KR Medical Equipment Branchendurchschnitt (16.1x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is A214150's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 31.3x |
| Fair PE Ratio | 23.8x |
PM vs. Fair Ratio: A214150 ist teuer auf der Grundlage des Verhältnisses Price-To-Earnings (22.8x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (18.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ₩36,700.00 | ₩44,555.56 +21.4% | 5.8% | ₩48,000.00 | ₩40,000.00 | n/a | 9 |
| Mar ’25 | ₩32,150.00 | ₩44,375.00 +38.0% | 6.1% | ₩48,000.00 | ₩40,000.00 | n/a | 8 |
| Feb ’25 | ₩29,350.00 | ₩45,375.00 +54.6% | 4.4% | ₩48,000.00 | ₩41,000.00 | n/a | 8 |
| Jan ’25 | ₩37,750.00 | ₩42,555.56 +12.7% | 13.5% | ₩48,000.00 | ₩30,000.00 | n/a | 9 |
| Dec ’24 | ₩41,600.00 | ₩42,888.89 +3.1% | 14.1% | ₩50,000.00 | ₩30,000.00 | n/a | 9 |
| Nov ’24 | ₩33,050.00 | ₩41,888.89 +26.7% | 12.9% | ₩47,000.00 | ₩30,000.00 | n/a | 9 |
| Oct ’24 | ₩37,850.00 | ₩41,555.56 +9.8% | 13.6% | ₩50,000.00 | ₩30,000.00 | n/a | 9 |
| Sep ’24 | ₩38,550.00 | ₩38,500.00 -0.1% | 14.6% | ₩50,000.00 | ₩30,000.00 | n/a | 8 |
| Aug ’24 | ₩29,600.00 | ₩37,000.00 +25.0% | 16.4% | ₩50,000.00 | ₩30,000.00 | n/a | 8 |
| Jul ’24 | ₩32,300.00 | ₩32,000.00 -0.9% | 15.7% | ₩40,000.00 | ₩24,000.00 | n/a | 6 |
| Jun ’24 | ₩27,200.00 | ₩29,000.00 +6.6% | 13.1% | ₩36,000.00 | ₩24,000.00 | n/a | 6 |
| May ’24 | ₩23,700.00 | ₩25,200.00 +6.3% | 3.0% | ₩26,000.00 | ₩24,000.00 | n/a | 5 |
| Apr ’24 | ₩21,750.00 | ₩24,000.00 +10.3% | 3.7% | ₩25,000.00 | ₩23,000.00 | ₩38,100.00 | 5 |
| Mar ’24 | ₩20,400.00 | ₩24,000.00 +17.6% | 3.7% | ₩25,000.00 | ₩23,000.00 | ₩32,150.00 | 5 |
| Feb ’24 | ₩18,390.00 | ₩23,000.00 +25.1% | 2.7% | ₩24,000.00 | ₩22,000.00 | ₩29,350.00 | 5 |
| Jan ’24 | ₩18,400.00 | ₩26,333.33 +43.1% | 28.4% | ₩43,000.00 | ₩22,000.00 | ₩37,750.00 | 6 |
| Dec ’23 | ₩18,850.00 | ₩26,571.43 +41.0% | 26.1% | ₩43,000.00 | ₩22,000.00 | ₩41,600.00 | 7 |
| Nov ’23 | ₩15,700.00 | ₩27,000.00 +72.0% | 25.8% | ₩42,000.00 | ₩22,000.00 | ₩33,050.00 | 6 |
| Oct ’23 | ₩13,500.00 | ₩27,000.00 +100.0% | 25.8% | ₩42,000.00 | ₩22,000.00 | ₩37,850.00 | 6 |
| Sep ’23 | ₩14,050.00 | ₩27,000.00 +92.2% | 25.8% | ₩42,000.00 | ₩22,000.00 | ₩38,550.00 | 6 |
| Aug ’23 | ₩16,000.00 | ₩27,333.33 +70.8% | 20.3% | ₩39,000.00 | ₩23,000.00 | ₩29,600.00 | 6 |
| Jul ’23 | ₩14,400.00 | ₩27,333.33 +89.8% | 20.3% | ₩39,000.00 | ₩23,000.00 | ₩32,300.00 | 6 |
| Jun ’23 | ₩17,600.00 | ₩26,714.29 +51.8% | 20.1% | ₩39,000.00 | ₩23,000.00 | ₩27,200.00 | 7 |
| May ’23 | ₩20,750.00 | ₩26,857.14 +29.4% | 18.5% | ₩38,000.00 | ₩22,000.00 | ₩23,700.00 | 7 |
| Apr ’23 | ₩23,350.00 | ₩26,285.71 +12.6% | 19.6% | ₩38,000.00 | ₩22,000.00 | ₩21,750.00 | 7 |
Analysten-Prognose: Das Kursziel liegt mehr als 20% über dem aktuellen Aktienkurs, und die Analysten liegen in einem statistisch sicheren Bereich der Übereinstimmung.